Drugs / MB07133
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06141109 | Jan 2022 → Jul 2024 | — | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT00073736 | Sep 2003 → Jul 2007 | hepatocellular carcinoma | Ligand Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06141096 | Jan 2020 → Jun 2024 | — | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB07133 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06141096 ↗ |
| Modality | Small molecule | — CHEMBL218922 ↗ |
| Route | Intravenous | “when administered as a 7-day continuous i.v.” NCT00073736 ↗ |